Synthesis and Anticandidal Activities of Some Aryl (5-Chloro-Benzofuran- 2-yl) Ketoximes

Author(s): Ahmet Cagri Karaburun*.

Journal Name: Letters in Drug Design & Discovery

Volume 16 , Issue 4 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: In this study, some aryl (5-chloro-benzofuran-2-yl) ketoximes and their ethers were synthesised to evaluate their antifungal activity against C. albicans, C. glabrata, C. krusei, and C. parapsilosis.

Methods: The structure elucidation of the compounds was performed by IR, 1H-NMR, 13C-NMR and HR-MS spectroscopic data. ADME parameters of synthesised compounds 2a-2d, 3a-3d, 4a-4d were predicted by an in-silico study and it was determined that all synthesised compounds may have a good pharmacokinetic profile.

Results: In the anticandidal activity studies, compounds 2c and 3c were found to be the most active compounds. The effect of compound 2c, on ergosterol biosynthesis of C. albicans, was determined by using the LC-MS-MS method.

Conclusion: It was also docked in the active site of the lanosterol 14α-demethylase enzyme, and shown that there is a strong interaction between compound 2c and enzyme.

Keywords: Aryl (5-chloro-benzofuran-2-yl) ketoximes, Anticandidal activity, Ergosterol inhibition, 14-alpha demethylase, docking study, antifungal activity.

[1]
Turner, S.J.; Senol, E.; Kara, A.; Al-Badriyeh, D.; Kong, D.C.; Dinleyici, E.C. Pharmacoeconomic evaluation of caspofungin versus liposomal amphotericin B in empirical treatment of invasive fungal infections in Turkey. Int. J. Antimicrob. Agents, 2013, 42(3), 276-280.
[2]
Chong, P.P.; Kennedy, C.C.; Hathcock, M.A.; Kremers, W.K.; Razonable, R.R. Epidemiology of invasive fungal infections in lung transplant recipients on long-term azole antifungal prophylaxis. Clin. Transplant., 2015, 29(4), 311-318.
[3]
Saliba, F.; Delvart, V.; Ichai, P.; Kassis, N.; Botterel, F.; Mihaila, L.; Azoulay, D.; Adam, R.; Castaing, D.; Bretagne, S.; Samuel, D. Fungal infections after liver transplantation: Outcomes and risk factors revisited in the MELD era. Clin. Transplant., 2013, 27(4), E454-E461.
[4]
Dos Santos, A.P.M.; McArthur, C.P.; Africa, C.W. Multi-drug resistant oral Candida species isolated from HIV-positive patients in South Africa and Cameroon. Diagn. Microbiol. Infect. Dis., 2014, 79(2), 222-227.
[5]
Healey, K.R.; Zhao, Y.; Perez, W.B.; Lockhart, S.R.; Sobel, J.D.; Farmakiotis, D.; Kontoyiannis, D.P.; Sanglard, D.; Taj-Aldeen, S.J.; Alexander, B.D. etal Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance. Nat. Commun., 2016, 7, 11128.
[6]
Dimopoulos, G.; Koulenti, D.; Tabah, A.; Poulakou, G.; Vesin, A.; Arvaniti, K.; Lathyris, D.; Matthaiou, D.; Armaganidis, A.; Timsit, J. Bloodstream infections in ICU with increased resistance: epidemiology and outcomes. Minerva Anestesiol., 2015, 81(4), 405-418.
[7]
Ravu, R.R.; Chen, Y.L.; Jacob, M.R.; Pan, X.; Agarwal, A.K.; Khan, S.I.; Heitman, J.; Clark, A.M.; Li, X.C. Synthesis and antifungal activities of miltefosine analogs. Bioorg. Med. Chem. Lett., 2013, 23(17), 4828-4831.
[8]
Miyazaki, M.; Horii, T.; Hata, K.; Watanabe, N.A.; Nakamoto, K.; Tanaka, K.; Shirotori, S.; Murai, N.; Inoue, S.; Matsukura, M. Abe, S.; Yoshimatsu, K.; Asada, M. In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds. Antimicrob. Agents Chemother., 2011, 55(10), 4652-4658.
[9]
He, S.; Jain, P.; Lin, B.; Ferrer, M.; Hu, Z.; Southall, N.; Hu, X.; Zheng, W.; Neuenswander, B.; Cho, C.H.; Chen, Y.; Worlikar, S.A.; Aubé, J.; Larock, R.C.; Schoenen, F.J.; Marugan, J.J.; Liang, T.J.; Frankowski, K.J. High-throughput screening, discovery, and optimization to develop a benzofuran class of hepatitis C virus inhibitors. ACS Comb. Sci., 2015, 17(10), 641-652.
[10]
Allan, A.C.; Billinton, A.; Brown, S.H.; Chowdhury, A.; Eatherton, A.J.; Fieldhouse, C.; Giblin, G.M.; Goldsmith, P.; Hall, A.; Hurst, D.N.; Naylor, A.; Rawlings, D.A.; Sime, M.; Scoccitti, T.; Theobald, P.J. Discovery of a novel series of nonacidic benzofuran EP1 receptor antagonists. Bioorg. Med. Chem. Lett., 2011, 21(14), 4343-4348.
[11]
Hassan, G.S.; Abou-Seri, S.M.; Kamel, G.; Ali, M.M. Celecoxib analogs bearing benzofuran moiety as cyclooxygenase-2 inhibitors: Design, synthesis and evaluation as potential anti-inflammatory agents. Eur. J. Med. Chem., 2014, 76, 482-493.
[12]
Mostofi, M.; Mohammadi, Z.G.; Mahdavi, M.; Moradi, A.; Nadri, H.; Emami, S.; Alinezhad, H.; Foroumadi, A.; Shafiee, A. Synthesis and structure-activity relationship study of benzofuran-based chalconoids bearing benzylpyridinium moiety as potent acetylcholinesterase inhibitors. Eur. J. Med. Chem., 2015, 103, 361-369.
[13]
Sashidhara, K.V.; Modukuri, R.K.; Jadiya, P.; Dodda, R.P.; Kumar, M.; Sridhar, B.; Kumar, V.; Haque, R.; Siddiqi, M.I.; Nazir, A. Benzofuran-chalcone hybrids as potential multifunctional agents against Alzheimer’s disease: Synthesis and in vivo studies with transgenic Caenorhabditis elegans. ChemMedChem, 2014, 9(12), 2671-2684.
[14]
Davis, L.; Agnew, M.N.; Effland, R.C.; Klein, J.T.; Kitzen, J.M.; Schwenkler, M.A. 2,3-Dihydro-3-(1-pyrryl)spiro[benzofuran-2,4′-piperidine]s and 2,3-dihydro-3-(1-pyrryl)spiro[benzofuran-2,3′-pyrrolidine]s: Novel antihypertensive agents. J. Med. Chem., 1983, 26(10), 1505-1510.
[15]
Li, W.; Yang, Z.H.; Hu, A.X.; Yan, X.W.; Ding, N.; Ye, J. Design, synthesis, and antitumor activity of (E,Z)-1-(dihydrobenzofuran-5-yl)-3-phenyl-2-(1,2,4-triazol-1-yl)-2-propen-1-ones. Chem. Biol. Drug Des., 2015, 86(6), 1339-1350.
[16]
Bazin, M.A.; Bodero, L.; Tomasoni, C.; Rousseau, B.; Roussakis, C.; Marchand, P. Synthesis and antiproliferative activity of benzofuran-based analogs of cercosporamide against non-small cell lung cancer cell lines. Eur. J. Med. Chem., 2013, 69, 823-832.
[17]
Mathews, M.; Gommoll, C.; Chen, D.; Nunez, R.; Khan, A. Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: A randomized, double-blind, placebo-controlled trial. Int. Clin. Psychopharmacol., 2015, 30(2), 67-74.
[18]
Grover, C.; Arora, P.; Manchanda, V. Comparative evaluation of griseofulvin, terbinafine and fluconazole in the treatment of tinea capitis. Int. J. Dermatol., 2012, 51(4), 455-458.
[19]
Shemer, A.; Plotnik, I.B.; Davidovici, B.; Grunwald, M.H.; Magun, R.; Amichai, B. Treatment of tinea capitis - griseofulvin versus fluconazole - a comparative study. J. Dtsch. Dermatol. Ges., 2013, 11(8), 737-742.
[20]
Wallace, S.M. Topically applied antifungal agents. Arch. Dermatol., 1977, 113, 11.
[21]
Zhai, M.; Wang, L.; Liu, S.; Wang, L.; Yan, P.; Wang, J.; Zhang, J.; Guo, H.; Guan, Q.; Bao, K.; Wu, Y.; Zhang, W. Synthesis and biological evaluation of (1-aryl-1H-pyrazol-4-yl) (3,4,5-trimethoxyphenyl)methanone derivatives as tubulin inhibitors. Eur. J. Med. Chem., 2018, 156, 137-147.
[22]
Xue, W.; Song, B.; He, W.; Wang, H.; Yang, S.; Jin, L.; Hu, D.; Liu, G.; Lu, P. Synthesis and biological activity of novel 1-(2,3,4-trimethoxyphenyl)-2-[5-(3,4,5-trimethoxyphenyl)-1,3,4-thiadiazol-2-yl]thioethanone oxime ester derivatives. J. Heterocycl. Chem., 2006, 43(4), 867-871.
[23]
Tu, S.; Xu, L-H.; Ye, L-Y.; Wang, X.; Sha, Y.; Xiao, Z-Y. Synthesis and fungicidal activities of novel indene-substituted oxime ether strobilurins. J. Agric. Food Chem., 2008, 56(13), 5247-5253.
[24]
Kamble, R.R.; Belgur, S.S.; Aladkatti, R.; Khazi, I.A. Synthesis and evaluation of benzophenone oximes derivatized with sydnone as inhibitors of secretory phospholipase A2 with anti-inflammatory activity. Chem. Pharm. Bull. , 2009, 57(1), 16-21.
[25]
Kirilmis, C.; Ahmedzade, M.; Servi, S.; Koca, M.; Kizirgil, A.; Kazaz, C. Synthesis and antimicrobial activity of some novel derivatives of benzofuran: Part 2. The synthesis and antimicrobial activity of some novel 1-(1-benzofuran-2-yl)-2-mesitylethanone derivatives. Eur. J. Med. Chem., 2008, 43(2), 300-308.
[26]
Ahluwalia, V.; Kumar, J.; Rana, V.S.; Singh, R.; Sati, O.P.; Walia, S.; Garg, N. Synthesis and antimicrobial activity of esters of 3-ethoxy-4-hydroxybenzaldehyde oxime. Toxicol. Environ. Chem., 2016, 99(1), 1-9.
[27]
Dai, H.; Chen, J.; Li, H.; Dai, B.; He, H.; Fang, Y.; Shi, Y. Synthesis and bioactivities of novel pyrazole oxime derivatives containing a 5-trifluoromethylpyridyl moiety. Molecules, 2016, 21(3), 276.
[28]
Behrouz, S.; Rad, M.N.; Rostami, S.; Behrouz, M.; Zarehnezhad, E.; Zarehnezhad, A. Design, synthesis, and biological activities of novel azole-bonded beta-hydroxypropyl oxime O-ethers. Mol. Divers., 2014, 18(4), 797-808.
[29]
Kosmalski, T.; Kutkowska, J.; Gzella, A.K.; Nowakiewicz, A. New heterocyclic oxime ethers of 1-(benzofuran-2-yl) ethan-1-one and their antimicrobial activity. Acta Pol. Pharm., 2015, 72, 289-295.
[30]
Kurt, A.; Bolat, Z.; Kırılmış, C. Synthesis, characterization and thermal decomposition kinetics of a novel benzofuran ketoxime derived polymer. Acta Chim. Slov., 2015, 62(2), 428-436.
[31]
Xie, Y.Q.; Huang, Y.B.; Liu, J.S.; Ye, L.Y.; Che, L.M.; Tu, S.; Liu, C.L. Design, synthesis and structure-activity relationship of novel oxime ether strobilurin derivatives containing substituted benzofurans. Pest Manag. Sci., 2015, 71(3), 404-414.
[32]
Pestellini, V.; Giolitti, A.; Pasqui, F.; Abelli, L.; Cutrufo, C.; Desalvia, G.; Evangelista, S.; Meli, A. Synthesis and hypolipidemic activity of new substituted (benzofuran-2-yl)-phenyl-carbinols. Eur. J. Med. Chem., 1988, 23(2), 203-206.
[33]
Rodriguez-Tudela, J.L.; Arendrup, M.C.; Barchiesi, F.; Bille, J.; Chryssanthou, E.; Cuenca-Estrella, M.; Dannaoui, E.; Denning, D.W.; Donnelly, J.P.; Dromer, F.; Fegeler, W.; Lass-Flörl, C.; Moore, C.; Richardson, M.; Sandven, P.; Velegraki, A.; Verweij, P. EUCAST definitive document EDef 7.1: Method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin. Microbiol. Infect., 2008, 14(4), 398-405.
[34]
Osmaniye, D.; Kaya, C.B.; Saglik, B.N.; Levent, S.; Acar, C.U.; Atli, O.; Ozkay, Y.; Kaplancikli, Z.A. Synthesis and anticandidal activity of new imidazole-chalcones. Molecules, 2018, 23, 4.
[35]
Levent, S.; Kaya, C.B.; Saglik, B.N.; Osmaniye, D.; Acar, C.U.; Atli, O.; Ozkay, Y.; Kaplancikli, Z.A. Synthesis of oxadiazole-thiadiazole hybrids and their anticandidal activity. Molecules, 2017, 22, 11.
[36]
Kaplancikli, Z.A.; Levent, S.; Osmaniye, D.; Saglik, B.N.; Cevik, U.A.; Cavusoglu, B.K.; Ozkay, Y.; Ilgin, S. Synthesis and anticandidal activity evaluation of new benzimidazole-thiazole derivatives. Molecules, 2017, 22, 12.
[37]
Cevik, U.A.; Saglik, B.N.; Ozkay, Y.; Canturk, Z.; Bueno, J.; Demirci, F.; Koparal, A.S. Synthesis of new fluoro-benzimidazole derivatives as an approach towards the discovery of novel intestinal antiseptic drug candidates. Curr. Pharm. Des., 2017, 23(15), 2276-2286.
[38]
Can, N.Ö.; Acar Çevik, U.; Sağlık, B.N.; Levent, S.; Korkut, B.; Özkay, Y.; Kaplancıklı, Z.A.; Koparal, A.S. Synthesis, molecular docking studies, and antifungal activity evaluation of new benzimidazole-triazoles as potential lanosterol 14α-demethylase inhibitors. J. Chem., 2017, 2017, 1-15.
[39]
Breivik, O.N.; Owades, J.L. Yeast analysis, spectrophotometric semimicrodetermination of ergosterol in yeast. J. Agric. Food Chem., 1957, 5(5), 360-363.
[40]
QikProp, version 4.8; Schrödinger, LLC: In New York, NY, 2016.
[41]
Hargrove, T.Y.; Friggeri, L.; Wawrzak, Z.; Qi, A.; Hoekstra, W.J.; Schotzinger, R.J.; York, J.D.; Guengerich, F.P.; Lepesheva, G.I. Structural analyses of Candida albicans sterol 14alpha-demethylase complexed with azole drugs address the molecular basis of azole-mediated inhibition of fungal sterol biosynthesis. J. Biol. Chem., 2017, 292(16), 6728-6743.
[42]
Maestro, version 10.6; Schrödinger, LLC: New York, NY, 2016.
[43]
Schrödinger, LLC; New York, NY 2016.
[44]
LigPrep, version 3.8; Schrödinger, LLC: New York, NY, 2016.
[45]
Glide, version 7.1; Schrödinger, LLC: New York, NY, 2016.
[46]
Borra, R.C.; Lotufo, M.A.; Gagioti, S.M.; Barros, F.M.
Andrade, P.M. A simple method to measure cell viability in proliferation and cytotoxicity assays. Braz. Oral Res., 2009, 23(3), 255-262.
[47]
Palomino, J.C.; Martin, A.; Camacho, M.; Guerra, H.; Swings, J.; Portaels, F. Resazurin microtiter assay plate: Simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2002, 46(8), 2720-2722.
[48]
Malik, M.A.; Al-Thabaiti, S.A.; Malik, M.A. Synthesis, structure optimization and antifungal screening of novel tetrazole ring bearing acyl-hydrazones. Int. J. Mol. Sci., 2012, 13(9), 10880-10898.
[49]
Dhingra, S.; Cramer, R.A. Regulation of sterol biosynthesis in the human fungal pathogen Aspergillus fumigatus: Opportunities for therapeutic development. Front. Microbiol., 2017, 8, 92.
[50]
Lupetti, A.; Danesi, R.; Campa, M.; Del Tacca, M.; Kelly, S. Molecular basis of resistance to azole antifungals. Trends Mol. Med., 2002, 8(2), 76-81.
[51]
Karaca, G.H.; Acar, C.U.; Levent, S.; Saglik, B.N.; Korkut, B.; Ozkay, Y.; Ilgin, S.; Ozturk, Y. New benzimidazole-1,2,4-triazole hybrid compounds: Synthesis, anticandidal activity and cytotoxicity evaluation. Molecules, 2017, 22, 4.
[52]
Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 1997, 23(1-3), 3-25.
[53]
Jorgensen, W.L.; Duffy, E.M. Prediction of drug solubility from structure. Adv. Drug Deliv. Rev., 2002, 54(3), 355-366.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 4
Year: 2019
Page: [427 - 436]
Pages: 10
DOI: 10.2174/1570180816666181207155701
Price: $58

Article Metrics

PDF: 22
HTML: 1
PRC: 1